UROV News and Press, Urovant Sciences Ltd. From 02/06/20

Urovant Sciences (Nasdaq: UROV) announced today that it will report 2019 third fiscal quarter financial results after the close of U.S. financial markets on Thursday, February 13, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pac...

Urovant Sciences (NASDAQ: UROV ) announces the publication, online in Neurology and Urodynamics , of results from two Phase 1 clinical trials evaluating gene therapy URO-902 in female patients with overactive bladder. More news on: Urovant Sciences Ltd., Healthcare stocks news, Read...

Urovant Sciences (Nasdaq: UROV) announced today the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder (OAB) from two double-blind, placebo-controlled randomized Phase 1 trials. The first trial was conducted with instillation therapy and the...

This article was highlighted for PRO+ subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here . Urovant Sciences (UROV) is a hidden gem—a significantly undervalued company that has been significantly de...

Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin and other Urovant executives will ring the opening bell of the Nasdaq Stock Market on Tuesday, January 21, 2020, at 9:30 a.m. Eastern. The ceremony will begin at 9:20 a.m. To view a live stream of ...

Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 4:30 p.m. Pacific / 7:30 p.m. Eastern on Wednesday, January 15, 2020, at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. A live, audio webcast for th...

Urovant Sciences (Nasdaq: UROV) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of once-daily 75mg vibegron for the treatment of patients with overactive bladder (OAB) with symptoms of urge urinary incontinen...

Urovant Sciences (NASDAQ: UROV ) has entered into a $300M term loan facility with Sumitomo Dainippon Pharma Co., Ltd. More news on: Urovant Sciences Ltd., Healthcare stocks news, Read more ...

Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that it has entered into a $300 million term loan facility with Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon Pharma”), a leading global Japanese pharmaceutical company. Urovant pl...

Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that its majority shareholder, Roivant Sciences Ltd. (“Roivant”), and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon Pharma”), a leading global Japanese pharmaceutical...